Skip to content

San Carlos, CA, October 18, 2021 – FlemingMartin is pleased to announce that Natera (NASDAQ: NTRA), a global pioneer in genetic testing and diagnostics, has hired Sean Ferree, Ph.D., as Vice President of Oncology IVD. Overseeing a team of senior product professionals at Natera, Sean now holds ownership of the oncology IVD product roadmap. In this post, Sean will provide product definition, management, strategic prioritization, technical leadership, and strategic vision for Natera’s current portfolio of IVD products, plus all future products.

Sean comes to Natera after spending the past 16+ years in roles of increasing responsibility at NanoString Technologies (NASDAQ: NSTG), a biotechnology company specializing in the development of translational research tools. Most recently, Sean held the position of Vice President of Customer Experience at NanoString. In this position, Sean drove a team of scientists and engineers dedicated to ensuring the success of life science research customers. Previously, he served as NanoString’s Vice President of Product Development and Vice President of Diagnostic Development, guiding the development of breakthrough technologies for translational research as well as in vitro diagnostics and companion diagnostics for oncology applications.

Among his many achievements at NanoString, Sean directed the team responsible for developing the Prosigna Gene Signature Assay. This accomplishment represented the first decentralized multi-gene expression signature for prognosis in early-stage breast cancer, and involved submitting and defending the test through regulatory clearance in both the U.S. and E.U. Sean earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and received his B.S. in Chemical Engineering from the University of Colorado, Boulder.


NateraNatera is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Natera’s Signatera technology is the first and only circulating tumor DNA (ctDNA) surveillance tool that detects molecular residual disease (MRD) for greater clinical confidence when assessing disease recurrence or treatment response in solid tumors. To learn more, visit



Fleming Martin Color Logo Small 72 PpiFlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.